$IONS News

BMO Capital Initiates Coverage On Ionis Pharmaceuticals with Market Perform Rating, Announces Price Target of $60

RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Ionis (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76

Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $115

Ionis Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...

Ionis Pharmaceuticals Q2 Earnings Call Highlights

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est

Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate